natgillin/translations-raw huggingface dataset:
The study showed beneficial effects of memantine treatment in comparison to placebo at 6 months (observed cases analysis for the clinician's interview based impression of change (CIBIC-plus): p=0.025; Alzheimer's disease cooperative study - activities of daily living (ADCS-ADLsev): p=0.003; severe impairment battery (SIB): p=0.002).
U 6. mjesecu ispitivanja pokazani su povoljni učinci liječenja memantinom u usporedbi s placebom (analiza opaženih slučajeva za promjene bazirane na dojmu kliničara nakon intervjua (CIBIC-plus): p=0,025; kooperativno ispitivanje Alzheimerove bolesti - aktivnosti svakodnevnog života (ADCS-ADLsev): p=0,003; skup znakova teške onesposobljenosti (SIB): p=0,002).
Memantine LEK should be administered orally once a day.
Memantine LEK treba primjenjivati kroz usta jedanput na dan.
When patients were identified with concurrent worsening in all three domains, results showed a statistically significant effect of memantine in preventing worsening, as twice as many placebo-treated patients as memantine-treated patients showed worsening in all three domains (21% vs. 11%,p<0.0001).
Kada je ustanovljeno istodobno pogoršanje stanja bolesnika u sva tri područja, rezultati su pokazali statistički značajan učinak memantina u sprječavanju pogoršanja, u skupini bolesnika liječenih placebom bilo je dvostruko više pogoršanja u sva tri područja nego u skupini bolesnika liječenih memantinom (21% naspram 11%, p<0,0001).
one and a half 10 mg tablets week 4 and beyond two 10 mg tablets or one 20 mg tablet once a day
4. tjedan i nadalje dvije tablete od 10 mg ili jedna tableta od 20 mg jedanput na dan
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IFAPPROPRIATE
POSEBNE MJERE ZA ZBRINJAVANJE NEISKORIŠTENOG LIJEKA ILI
What Memantine LEK looks like and contents of the pack Memantine LEK 10 mg film-coated tablets are presented as yellow, oval film-coated tablet scored in one side.
Kako Memantine LEK izgleda i sadržaj pakiranja Memantine LEK 10 mg filmom obložene tablete su žute boje, ovalnog oblika, urezane na jednoj strani.
Common (may affect up to 1 in 10 people):
Česte (mogu se javiti kod 1 na 10 osoba):
The recommended maintenance dose is 20 mg per day.
Preporučena doza održavanja je 20 mg dnevno.
Tablet core: croscarmellose sodium, colloidal anhydrous silica, microcrystalline cellulose, magnesium stearate
Jezgra tablete: umrežena karmelozanatrij, koloidni bezvodni silicijev dioksid, mikrokristalična celuloza, magnezijev stearat.
Somnolence Confusion Hallucinations1
Manje često konfuzija Manje često halucinacije1
Sandoz d.d Representative office Teл.
Sandoz d.d. representative office Latvia.
Uncommon (may affect up to 1 in 100 people):
Manje česte (mogu se javiti kod 1 na 100 osoba):
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER PACKING
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU KUTIJA ZA BLISTER
Memantine LEK belongs to a group of medicines called NMDA-receptor antagonists.
Memantine LEK spada u skupinu lijekova poznatih kao antagonisti NMDA
Memantine LEK 20 mg film-coated tablets are presented as pale red, oval film-coated tablet scored in one side.
Memantine LEK 20 mg filmom obložene tablete su blijedo crvene boje, ovalnog oblika, urezane na jednoj strani.
INFORMATION IN BRAILLE Memantine LEK 20 mg
16. PODACI NA BRAILLEOVOM PISMU Memantine LEK 20 mg
INFORMATION IN BRAILLE Memantine LEK 10 mg
16. PODACI NA BRAILLEOVOM PISMU Memantine LEK 10 mg
Animal studies indicate a potential for reducing intrauterine growth at exposure levels, which are identical or slightly higher than at human exposure (see section 5.3).
Nema podataka ili su podaci o primjeni memantina u trudnica ograničeni.Ispitivanja na životinjama upućuju na postojanje mogućnosti smanjenja intrauterinog rasta pri izloženosti dozama istim ili nešto višim nego što su kod ljudi (vidjeti dio 5.3).
In most clinical trials, patients with recent myocardial infarction, uncompensated congestive heart failure (NYHA III-IV), or uncontrolled hypertension were excluded.
nekompenzirano kongestivno zatajenje srca (NYHA III-IV) ili nekontroliranu hipertenziju.
Memantine LEK contains the active substance memantine hydrochloride.
Memantin LEK sadrži djelatnu tvar memantinklorid.
Memantine LEK is for oral use.
Memantin LEK je za peroralnu primjenu.
Constipation Vomiting Pancreatitis2
Nepoznato pankreatitis2
Marketing Authorisation Holder Pharmathen S.A., 6, Dervenakion str., 15351 Pallini, Attiki, Greece
Nositelj odobrenja za stavljanje lijeka u promet Pharmathen S.A., 6, Dervenakion str., 15351 Pallini, Attiki, Grčka
From the fourth week on, the usual dose is 2 tablets once a day (1 x 20 mg).
uobičajena doza je 2 tablete jedanput na dan (1 x 20 mg).
In this case, monitoring of your kidney function should be performed by your doctor at specified intervals.
U tom slučaju liječnik bi trebao u određenim razmacima nadzirati funkciju bubrega.
On the basis of the clinical studies, the recommended dose for patients over the age of 65 years is 20 mg per day as described above.
Temeljem kliničkih ispitivanja, preporučena doza za bolesnike starije od 65 godina iznosi 20 mg dnevno
Women taking Memantine LEK should not breast-feed.
Žene koje uzimaju Memantin LEK ne smiju dojiti.
Film-coating: polyvinyl alcohol, titanium dioxide (E-171), talc, macrogol 3350, iron oxide yellow (E172) and iron oxide red (E-172)
Film ovojnica: poli(vinilni alkohol), titanijev dioksid (E171), talk, makrogol 3350, žuti željezov oksid (E172) i crveni željezov oksid (E172).
Very Rare (may affect up to 1 in 10,000 people): • Seizures
Vrlo rijetke (mogu se javiti kod 1 na 10 000 osoba):
How to take Memantine LEK
Kako uzimati Memantine LEK
Common Common Uncommon Very rare
Manje često abnormalni hod Vrlo rijetko napadaji
amantadine, ketamine, dextromethorphan dantrolene, baclofen cimetidine, ranitidine, procainamide, quinidine, quinine, nicotine hydrochlorothiazide (or any combination with hydrochlorothiazide) anticholinergics (substances generally used to treat movement disorders or intestinal cramps) anticonvulsants (substances used to prevent and relieve seizures) barbiturates (substances generally used to induce sleep) dopaminergic agonists (substances such as L-dopa, bromocriptine) neuroleptics (substances used in the treatment of mental disorders) oral anticoagulants
amantadina, ketamina, dekstrometorfana dantrolena, baklofena cimetidina, ranitidina, prokainamida, kinidina, kinina, nikotina hidroklorotiazida (ili bilo koje kombinacije s hidroklorotiazidom)
Talk to your doctor or pharmacist before taking Memantine LEK
Upozorenja i mjere opreza Obratite se svom liječniku ili ljekarniku prije nego uzmete Memantin LEK.
There is increasing evidence that malfunctioning of glutamatergic neurotransmission, in particular at NMDA-receptors, contributes to both expression of symptoms and disease progression in neurodegenerative dementia.
NMDA-receptorima, doprinosi izraženosti simptoma i progresiji bolesti kod neurodegenerativne demencije.
NAME OF THE MARKETING AUTHORISATION HOLDER Pharmathen S.A.
NAZIV NOSITELJA ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET Pharmathen S.A.
Administration of Memantine LEK is not recommended in patients with severe hepatic impairment.
Ne preporučuje se primjena lijeka Memantine LEK kod bolesnika s teškim oštećenjem jetre.
Yellow, oval film-coated tablet scored in one side.
Žuta filmom obložena tableta ovalnog oblika urezana na jednoj strani.
The patient should take one 20 mg film-coated tablet (20 mg) per day for 7 days.
Bolesnik treba uzimati jednu filmom obloženu tabletu od 20 mg dnevno za 7 dana.
• There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when memantine is coadministered with HCT or any combination with HCT.
• Pri istodobnoj primjeni memantina i hidroklorotiazida (HCT-a), ili bilo koje od kombinacija s
Pale red, oval film-coated tablet scored in one side.
Blijedo crvena filmom obložena tableta ovalnog oblika, urezana na jednoj strani.
What Memantine LEK is and what it is used for
Što je Memantine LEK i za što se koristi Kako djeluje Memantine LEK
In patients with severe renal impairment (creatinine clearance 5 - 29 mL/min) daily dose should be 10 mg per day.
Kod bolesnika s teškim oštećenjem bubrega (klirens kreatinina 5-29 mL/min) dnevna doza bi trebala biti
Pharmathen International S.A., Industrial Park Sapes, Rodopi Prefecture, Block No 5, Rodopi 69300, Greece Lek Pharmaceuticals d.d., Verovškova 57, 1526 Ljubljana, Slovenia
Pharmathen S.A , 6, Dervenakion str., 15351 Pallini, Attiki, Grčka Pharmathen International S.A., Industrial Park Sapes, Rodopi Prefecture, Block No 5, Rodopi 69300,
How to store Memantine LEK
Kako čuvati Memantine LEK
organizacna zlozka Tel: + 421-2/48 200 600
Slovenská republika Sandoz d.d. organizacna zlozka Tel: + 421-2/48 200 600
10 mg: Film-coating: polyvinyl alcohol, titanium dioxide (E-171), talc, macrogol 3350 and iron oxide yellow (E
Film ovojnica: poli(vinilni alkohol), titanijev dioksid (E171), talk, makrogol 3350 i žuti željezov oksid (E172).
Estonia Tel: + 372 6652405
Sandoz d.d. Estonia Tel: + 372 6652405
Each 20 mg tablet contains 20 mg of memantine hydrochloride equivalent to 16.62 mg memantine.
Jedna 20 mg tableta sadrži 20 mg memantinklorida što odgovara 16,62 mg memantina.
Package leaflet: Information for the user Memantine LEK 10 mg film-coated tablets Memantine LEK 20 mg film-coated tablets memantine hydrochloride
Uputa o lijeku: Informacije za korisnika Memantin LEK 10 mg filmom obložene tablete Memantin LEK 20 mg filmom obložene tablete memantinklorid
Each 10 mg tablet contains 10 mg of memantine hydrochloride equivalent to 8.31 mg memantine.
Jedna 10 mg tableta sadrži 10 mg memantinklorida što odgovara 8,31 mg memantina.
A pivotal monotherapy study in a population of patients suffering from moderate to severe Alzheimer's disease (mini mental state examination (MMSE) total scores at baseline of 3 - 14) included a total of 252 outpatients.
Alzheimerove bolesti (početne vrijednosti kratkog testa određivanja mentalnog statusa (MMSE) bile su 3-14) uključivalo je ukupno 252 ambulantna bolesnika.
PC:
Tel.:
Memantine-treated patients showed a statistically significantly better effect than placebo-treated patients on the primary endpoints: Alzheimer's disease assessment scale (ADAS-cog) (p=0.003) and CIBIC-plus (p=0.004) at week 24 last observation carried forward (LOCF).
Bolesnici liječeni memantinom pokazali su statistički značajno bolji učinak nego bolesnici koji su primali placebo u pogledu primarnih ishoda: skala procjene Alzheimerove bolesti (ADAS-cog) (p=0,003) i CIBIC-plus
Memantine LEK 20 mg film-coated tablets are available in PVC/PVDC-Aluminium blister packs of 28, 30, 42, 56, 98 and 100 tablets.
Memantine Lek 20 mg filmom obložene tablete su dostupne u PVC/PVDC-aluminij blister pakiranju sa 28, 30, 42, 56, 98 i 100 tableta.
EU/1/13/826 /007 28 film-coated tablets EU/1/13/826 /008 30 film-coated tablets EU/1/13/826 /009 42 film-coated tablets EU/1/13/826 /010 56 film-coated tablets EU/1/13/826 /011 98 film-coated tablets EU/1/13/826 /015 100 film-coated tablets
EU/1/13/826 /007 28 filmom obloženih tableta EU/1/13/826 /008 30 filmom obloženih tableta EU/1/13/826 /009 42 filmom obloženih tableta EU/1/13/826 /010 56 filmom obloženih tableta EU/1/13/826 /011 98 filmom obloženih tableta EU/1/13/826 /015 100 filmom obloženih tableta
QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 20 mg of memantine hydrochloride equivalent to 16.62 mg memantine.
KVALITATIVNI I KVANTITATIVNI SASTAV Jedna filmom obložena tableta sadrži 20 mg memantinklorida, što odgovara 16,62 mg memantina.
In clinical trials in mild to severe dementia, involving 1,784 patients treated with memantine and 1,595 patients treated with placebo, the overall incidence rate of adverse reactions with memantine did not differ from those with placebo; the adverse reactions were usually mild to moderate in severity.
1595 ih je dobivalo placebo, sveukupna stopa incidencije nuspojava u skupini liječenoj memantinom nije se razlikovala od stope incidencije nuspojava u skupini koja je primala placebo.
Memantine LEK 10 mg film-coated tablets are available in PVC/PVDC-Aluminium blister packs of 28, 30, 42, 50, 56, 60, 98, 100 and 112 tablets.
Memantine Lek 10 mg filmom obložene tablete su dostupne u PVC/PVDC-aluminij blister pakiranju sa 28, 30, 42, 50, 56, 60, 98, 100 i 112 tableta.
These factors include drastic changes in diet, e.g. from a carnivore to a vegetarian diet, or a massive ingestion of alkalising gastric buffers.
prelazak s mesne na vegetarijansku prehranu ili uzimanje izrazito velike količine alkalizirajućih želučanih pufera.
NAME OF THE MEDICINAL PRODUCT Memantine LEK 10 mg film-coated tablets
NAZIV LIJEKA Memantin LEK 10 mg filmom obložene tablete
Tel: + 386 1 580 3327
Lek Pharmaceuticals d.d. Tel: + 386 1 580 3327
Aluminium-PVC/PVDC blisters placed into cardboard boxes containing 28, 30, 42, 50, 56, 60, 98, 100 and 112 film-coated tablets.
Aluminij-PVC/PVDC blisteri, pakirani u kartonske kutije koje sadrže 28, 30, 42, 50, 56, 60, 98, 100 i 112 filmom obloženih tableta.
NAME OF THE MEDICINAL PRODUCT Memantine LEK 20 mg film-coated tablets
NAZIV LIJEKA Memantin LEK 20 mg filmom obložene tablete
half 10 mg tablet week 2
1. tjedan pola tablete od 10 mg
Aluminium-PVC/PVDC blisters placed into cardboard boxes containing 28, 30, 42, 56, 98 and 100 filmcoated tablets.
Aluminij-PVC/PVDC blisteri, pakirani u kartonske kutije koje sadrže 28, 30, 42, 56, 98 i 100 filmom obloženih tableta.
Tel: + +420 225 775 111
Sandoz s.r.o. Tel: + +420 225 775 111
P.T.Hadjigeorgiou Co Ltd Τηλ: + 357 - 25372425
Τηλ: + 357 - 25372425
NAME OF THE MEDICINAL PRODUCT Memantine LEK 20 mg film-coated tablets memantine hydrochloride
Memantine LEK 20 mg filmom obložene tablete memantinklorid
In another monotherapy study in mild to moderate Alzheimer's disease a total of 470 patients (MMSE total scores at baseline of 11-23) were randomised.
U drugom monoterapijskom ispitivanju blage do umjerene Alzheimerove bolesti randomizirano je ukupno 470
Do not take Memantine LEK
Ako ste zaboravili uzeti Memantine LEK
On the basis of the clinical studies, the recommended dose for patients over the age of 65 years is 20 mg per day (two 10 mg tablets once a day) as described above.
Temeljem kliničkih ispitivanja, preporučena doza za bolesnike starije od 65 godina iznosi 20 mg na dan,
Slovenská republika Sandoz d.d.
Sandoz d.d Representative office
NAME OF THE MEDICINAL PRODUCT Memantine LEK 10 mg film-coated tablets memantine hydrochloride
Memantin LEK 10 mg filmom obložene tablete memantinklorid
Iron oxide yellow (E 172) Iron oxide red (E 172)
Ovojnica tablete poli(vinilni alkohol) makrogol 3350 titanijev dioksid (E 171) Talk željezov oksid, žuti (E 172) željezov oksid, crveni (E 172)
STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 20 mg memantine hydrochloride equivalent to 16.62 mg memantine.
Jedna filmom obložena tableta sadrži 20 mg memantinklorida, što odgovara 16,62 mg memantina.
STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 10 mg memantine hydrochloride equivalent to 8.31 mg memantine.
Jedna filmom obložena tableta sadrži 10 mg memantinklorida, što odgovara 8,31 mg memantina.
Dose
Raspodjela
Dyspnoea
Doziranje
Tablet coat
IME NOSITELJA
Generally one kit is sufficient.
Općenito dovoljan je jedan komplet.
It can be used in the following situations:
Može se koristiti u sljedećim situacijama:
• patients who are still growing;
• bolesnicima koji još uvijek rastu;
This summary was last updated in 02-2015.
Sažetak je posljednji put obnovljen 02.2015.
The full EPAR for Inductos can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Cjeloviti EPAR nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
• treating a fracture that is related to a disease such as Paget's disease or cancer.
• liječenje frakture koje je povezano s bolešću, poput Pagetove bolesti ili raka.
Inductos must not be used in the following situations:
Inductos se ne smije primjenjivati u sljedećim situacijama:
After two years, 57% of the patients treated with Inductos (69 out of 122) had responded to treatment, compared with 59% of the patients treated with a bone graft (78 out of 133).
Nakon dvije godine, 57% bolesnika liječenih lijekom Inductos (69 od 122) odgovorilo je na terapiju, u usporedbi s 59% bolesnika liječenih koštanim presatkom (78 od 133).
The newly formed bone grows into the matrix, which then degrades.
Novoformirana kost raste u matricu, koja zatim degradira.
In addition, the company that markets Inductos will make sure that educational material is available in all Member States for all healthcare professionals expected to use the medicine.
Nadalje, tvrtka koja stavlja Inductos u promet osigurat će dostupnost edukacijskih materijala u svim državama članicama za sve zdravstvene djelatnike za koje se očekuje da će ih koristiti.
The matrix is then cut, if needed, to the correct size before use.
Matrica se zatim prije uporabe izrezuje na ispravnu veličinu.
The European Commission granted a marketing authorisation valid throughout the European Union for Inductos on 9 September 2002.
Europska komisija izdaje odobrenje za stavljanje u promet koje za lijek Inductos vrijedi na prostoru Europske unije od 9. rujna 2002.
• patients diagnosed with or being treated for cancer;
• bolesnicima kojima je dijagnosticiran ili koji se liječe od raka;
• patients with an inadequate blood supply at the fracture site;
• bolesnicima s neprimjerenom opskrbom krvlju u mjestu frakture;
What measures are being taken to ensure the safe and effective use of Inductos?
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Inductos?
Dibotermin alfa is produced by a method known as ‘recombinant DNA technology': it is made by cells that have received a gene (DNA) which makes them able to produce dibotermin alfa.
Dibotermin alfa je proizveden metodom poznatom pod nazivom "tehnologija rekombinantne DNK": proizvode ju stanice koje su zaprimile gen (DNK) koji im zatim omogućuje stvaranje dibotermin alfa.
This is a summary of the European public assessment report (EPAR) for Inductos.
Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Inductos.
Other information about Inductos
Ostale informacije o lijeku Inductos
It is a copy of a protein called bone morphogenetic protein 2 (BMP-2), which is produced naturally by the body and helps with the formation of new bone tissue.
To je kopija proteina naziva morfogenetski protein 2 (BMP-2), kojeg tijelo prirodno proizvodi i pomaže s formiranjem novog koštanog tkiva.
In this type of surgery, Inductos can be used instead of an autogenous bone graft (bone taken from one part of a person's body and placed in another part of the body).
U ovom tipu kirurškog zahvata, Inductos se može koristiti umjesto autogenog presatka kosti (kosti uzete iz jednog dijela tijela osobe i stavljene u drugi dio tijela).
For more information about treatment with Inductos, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Više informacija o terapiji lijekom Inductos pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
Inductos is used together with approved medical devices that correct the position of the spine.
Inductos se koristi zajedno s odobrenim medicinskim proizvodima koji ispravljaju položaj kralježnice.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Inductos.
Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenio lijek da bi donio svoje mišljenje u korist izdavanja odobrenja za stavljanje lijeka u promet i svoje preporuke za uporabu lijeka Inductos.
Inductos has been studied in 450 patients with a fractured tibia.
Inductos je ispitan u 450 bolesnika s frakturom tibije.
Inductos is made up into a solution before use, applied to the matrix and left for at least 15 minutes (but no more than two hours).
Prije uporabe treba pripremiti otopinu lijeka Inductos, primijeniti otopinu na matricu i ostaviti na najmanje 15 minuta (no ne više od dva sata).
This material will include information on the risk of heterotopic ossification and the potential risk of medication errors and incorrect use of Inductos.
Ovi materijali će obuhvatiti informacije o riziku heterotopične osifikacije te potencijalnom riziku pogreška pri primjeni lijeka i neispravnoj primijeni Inductos.
Of the patients in the standard care group, 46% needed a further intervention within a year to repair their fracture, while the proportion was 26% for those also receiving Inductos.
Od svih bolesnika koji su bili u grupi koja je primala standardnu skrb, u 46% bolesnika bila je potrebna dodatna intervencija unutar godine dana kako bi se popravila njihova fraktura u odnosu na 26% onih koji su primili Inductos.
The most common side effects with Inductos (seen in more than 1 patient in 10) are radiculopathic events (problems occurring at or near the root of the nerve, along the spine, resulting in pain, weakness, numbness, or difficulty controlling specific muscles) when used in spine surgery, and localised infection when used in tibia fracture surgery.
Najčešće nuspojave Inductos (mogu se javiti u više od 1 na 10 osoba) su radikulopatijski događaji (problemi koji nastupaju u ili blizini korijena živca, uz kralježnicu, što rezultira boli, slabošću, utrnućem ili poteškoćama pri kontroliranju određenih mišića) ako se koriste u kiruškom zahvatu na kralježnici, i lokalizirane infekcije ako se koriste u kirurškom zahvatu za popravak frakture tibije.
The main measure of effectiveness was fusion of the vertebrae confirmed by X-ray, and improvement in the pain and disability reported by the patient, measured two years after surgery.
Glavna mjera djelotvornosti bila je fuzija kralješka potvrđena rendgenskim zrakama, te poboljšanje u boli i invaliditetu prijavljeno od strane bolesnika, izmjereno dvije godine nakon kirurškog zahvata.
A risk management plan has been developed to ensure that Inductos is used as safely as possible.
Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Inductos.
The main measure of effectiveness was the number of patients who did not need further treatment for their fractured tibia (such as a bone graft or changes to the nail used to fix the bones together) in the year following surgery.
Glavna mjera djelotvornosti bio je broj bolesnika kojima nije bila potrebna daljnja terapija za liječenje frakture tibije (poput koštanog prestaka ili promjene u čavlu korištenom za fiksiranje kostiju) u godini nakon kirurškog zahvata.
Additional studies and analysis of data from the published literature showed that Inductos was more effective than bone graft at inducing fusion of the lower back vertebrae, irrespective of the surgical technique or the type of approved medical device used to hold the bone in position.
Dodatna ispitivanja i analiza podataka iz objavljene literature pokazala su da je Inductos djelotvorniji od koštanog prestaka u poticanju fuzije lumbalne kralježnice, bez obzira na primijenjenu kiruršku tehniku ili tip odobrenih medicinskih proizvoda koji su korišteni za držanje kosti u mjestu.
The replacement dibotermin alfa acts in same way as BMP-2 produced naturally by the body.
Zamjenski dibotermin alfa djeluje na isti način kao BMP-2 proizveden prirodnim putem od strane tijela.
It is only used when the nail to fix the bone does not need ‘reaming' (drilling to make room for nail placement).
Koristi se samo u slučajevima kada nije potrebno ponovno "ciljanje" čavla za fiksiranje kosti (bušenje kako bi se napravilo mjesta za postavljanje čavla).
Inductos is used in adults who have been treated for at least six months for back pain due to a damaged disc but have not had an operation.
Inductos se koristi u odraslih osoba koje su liječene u posljednjih šest mjeseci protiv boli u leđima uslijed ozljede diska, no nisu imale kirurški zahvat.